Clinical Trial

US: Most effective dose of vaccine for preventing Cytomegalovirus (CMV)

We are inviting individuals living in the United States to join very important clinical trial, designed to evaluate the most effective dose of vaccine for preventing Cytomegalovirus (CMV) in children 9 to 17 and adults 18 to 25. Potential participants should be in good health and able to follow instructions to participate in the clinical trial presented by the staff.

Moderna is committed to researching safe and effective mRNA-based vaccines and therapies to bring better health and living to people of all ages, sexes, and backgrounds.

  • Location: United States
  • Date: As soon as possible, until December 2023
  • Incentive: To be disclosed by the client
  • Availability: 770 slots available